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Atomoxetine Treatment in Children and
Adolescents with Attention-Deficit
Hyperactivity Disorder: What Are the Long-Term
Health-Related Quality-of-Life Outcomes?
Amy R. Perwien, Ph.D.,1 Christopher J. Kratochvil, M.D.,2 Douglas E. Faries, Ph.D.,1
Brigette S. Vaughan, B.S.N.,2 Thomas Spencer, M.D.,3 and Ronald T. Brown, Ph.D.4

ABSTRACT
Objective: Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively
few studies have addressed the impact of treatment on long-term subjective, psychosocial
outcomes, such as health-related quality of life (HRQL). This study examines the long-term
effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents
with ADHD.
Methods: Participants included 6- to 17-year-old children and adolescents (n = 912) with
ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of
HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated
based on a CHQ improvement of at least 1 standard error of measurement.
Results: Significant improvements in HRQL were found following both acute and long-term
treatment for psychosocial but not physical health. Of participants who completed treatment (n
= 312 or 34.2% of those enrolled), 81% responded to acute treatment and 78% responded to longterm treatment. Improvements noted after acute treatment were maintained during long-term
treatment with the majority of participants (86%) continuing to respond to treatment.
Conclusions: Atomoxetine is associated with improvements in HRQL, and the improvements are generally stable over time.

INTRODUCTION

A

TTENTION-DEFICIT/HYPERACTIVITY

DISORDER

(ADHD) is a frequently occurring childhood mental health disorder that often results

in a number of functional impairments including academic difficulties (Faraone et al. 2001;
Pastor and Reuben 2002), social skills deficits
(Bagwell et al. 2001; Greene et al. 2001;
Thurber et al. 2002), and strained family rela-
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tionships (Johnston and Mash 2001). In addition, longitudinal studies have indicated that
ADHD is associated with higher rates of substance use (Weiss et al. 1985; Biederman et al.
1998; Tapert et al. 2002) as well as lower academic and occupational attainment (Mannuzza et al. 1997; Hansen et al. 1999; Barkley et
al. 2002).
Given the impact of ADHD on multiple domains of functioning and the chronic nature of
the disorder, ADHD recently has been viewed
as a disorder that can significantly impact
health-related quality of life (HRQL). HRQL is
distinct from both disorder symptoms and
objective functional outcomes in that it is
multidimensional and subjectively examines
physical, social, and psychological aspects of
health (Wallander et al. 2001). In children and
adolescents with ADHD, HRQL is related to
disease symptomatology, but provides information beyond that obtained from traditional
symptom measures (Matza et al. 2004). When
comparing children with ADHD to normative
data, worse HRQL in psychosocial health has
been noted in children with ADHD (Landgraf
et al. 1996). Consistent findings were found in
a large-scale study of Australian children and
adolescents (n = 3597), even after controlling
for age, gender, family structure, and health
status (Sawyer et al. 2002). These studies of
HRQL in children with ADHD suggest that
this is an important outcome that is not fully
captured by traditional ADHD symptom measures. Not surprisingly, studies have consistently indicated that the impact of ADHD on
HRQL seems to be specific to psychosocial
health as opposed to physical health (Landgraf
et al. 1996; Sawyer et al. 2002).
With regard to the management of ADHD
and its associated symptoms, pharmacotherapy
and behavior therapy are considered to be the
standard of care. In fact, a number of studies
have attested to the efficacy of these treatments
in the management of the disorder (for reviews,
see Pelham et al. 1998; Barkley 2002; Greenhill,
et al. 2002; Kratochvil et al., 2003). Although numerous studies have addressed the effect of
treatment on core ADHD symptoms, HRQL has
not been addressed as frequently in well-controlled trials of ADHD treatments. This is despite the fact that the American Academy of
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Pediatrics (AAP) has suggested that treatment
outcomes should include improved functionality as well as decreased core symptomatology
(American Academy of Pediatrics 2001). Some
of the functional improvements areas highlighted by the AAP can be captured by psychosocial aspects of HRQL measures as has
been done in double-blind, placebo-controlled
trials of atomoxetine. These trials have noted
that atomoxetine improved psychosocial
HRQL as well as core ADHD symptoms
(Michelson et al. 2001; Perwien et al. 2004).
Although well-designed long-term studies,
such as the landmark Multimodal Treatment
Study of Attention Deficit/Hyperactivity Disorder (MTA Cooperative Group, 1999), have
noted the effectiveness of medication treatment for core ADHD symptomatology, HRQL
has only recently been examined. A 9-month
randomized, double-blind, placebo-controlled
study of atomoxetine treatment responders
found that medication was superior to placebo
in improving HRQL as well as in maintaining
core ADHD symptom response (Michelson et
al. 2004).
In summary, research has shown both shortand long-term negative outcomes associated
with childhood ADHD. Although clinical trials have consistently supported the efficacy of
pharmacotherapy, less data are available on
the long-term effects of these medications.
Even though the psychosocial aspects of
HRQL have been identified as an area of concern for children with ADHD, few studies
have systematically examined the effect of
treatment on HRQL, let alone response to
long-term treatment. The present study builds
on earlier research that supported the positive
effect of acute treatment with atomoxetine on
HRQL. Although core symptom response to
atomoxetine was examined in this study, the
primary objective of this report is to investigate the long-term outcome of atomoxetine
treatment on HRQL. It was hypothesized that
psychosocial HRQL would improve following
10-week acute treatment and would be maintained over a 24-month treatment phase.
Given that previous research indicates poor
HRQL in ADHD is specifically associated with
psychosocial health, no changes in physical
health following treatment were expected.
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METHODS
Participants
Children and adolescents diagnosed with
ADHD who ranged in age from 6 to 17 years
were enrolled in a multicenter (55 sites), openlabel trial of atomoxetine. Participants were recruited through physician referrals and by
advertisement. To qualify for participation in
the study, participants had to meet diagnostic
and severity criteria for ADHD. Potential participants were excluded if they had a history of
bipolar disorder or psychosis (including use of
antipsychotic medication within 8 weeks of
study enrollment), cognitive impairment (i.e.,
IQ <80), seizure disorder, and/or significant
medical condition(s). Children also were excluded if they had a history of alcohol or drug
abuse within the past 3 months. Although a
history of psychotropic medication use was
permitted, participants were required to be
free of any psychotropic medication, including
stimulant medications, and health food supplements with purported central nervous system activity for at least 5 half lives prior to
study enrollment. For example, children had
to be free of short-acting stimulants for at least
24 hours and long-acting stimulants for 1–2
days (Concerta® and Adderall XR® for at least
17.5 hours and 48 hours, respectively).

Measures
Trained mental health providers (e.g., psychiatrists, psychologists) administered the
Schedule for Affective Disorders and Schizophrenia for School-Age Children–Present/
Lifetime Version (K-SADS-PL; Ambrosini 2000)
to document the presence of ADHD and to determine the subtype (combined, predominately
inattentive, predominately hyperactive/impulsive). The K-SADS-PL is a semistructured
psychiatric interview that allows the interviewer to incorporate data from multiple informants (i.e., parent and child) to determine
diagnoses. The behavioral (ADHD, oppositional defiant disorder, conduct disorder), affective, and anxiety disorder sections were
administered. The K-SADS has been found to
have adequate reliability and validity (Am-
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brosini 2000). To assess ADHD symptom severity, the clinician-rated version of the ADHD
Rating Scale (ADHD-RS; Faries et al. 2000) was
completed by trained mental health providers,
on the basis of an interview with the parent/
guardian, while the parents directly rated the
child’s behavior using the Conners’ Parent Rating Scale–Revised: Short-Form (CPRS-R:S; Conners 1997). The ADHD-RS includes 18 items,
each of which corresponds to a specific ADHD
symptom. For entry into the study, children
were required to be at least one standard deviation (SD) above the norm on the ADHD-RS for
their diagnostic subtype. The CPRS-R:S is a 27item rating scale that assesses behavioral problems related to ADHD and includes the
following subscales: ADHD Index, Hyperactivity, Cognitive Problems, and Oppositional.
To assess HRQL, the child’s caregiver completed the Child Health Questionnaire (CHQ)
(Landgraf et al. 1996). The CHQ is a generic
HRQL measure that has been used in studies
of children with a variety of chronic conditions
including ADHD (Landgraf et al. 1996; Sawyer
et al. 2002). Although a child self-report version of the CHQ exists, the parent version was
selected because it is more widely researched,
has normative data available, and may be used
with a broad age range (children 5–18 years of
age). The 50-item parent report version of the
CHQ includes two summary measures (physical and psychosocial health) and 11 domain
scales. Scales assessing physical functioning,
pain, physical role functioning, and health
perceptions address physical health. Scales
measuring emotional/behavioral role functioning, behavior, mental health, self-esteem,
parental time impact, parental emotional impact, and family functioning examine psychosocial health. The psychometric properties
of the CHQ are described fully in the test manual (Landgraf et al. 1996) and support the internal consistency ( = 0.66–0.94 for CHQ
scales), factor structure, and validity of the
measure. Higher scores on the CHQ signify
better HRQL.
Procedures
For each participating site, either an Institutional Review Board (IRB) at the site or a cen-
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tralized IRB approved the investigational procedures. Informed consent was obtained from
each participant’s parent or guardian and assent was obtained from each child. Following
the informed consent process, children were
evaluated to determine whether ADHD diagnostic and severity criteria were met without
the presence of any exclusionary criteria. During the first 10 weeks of the study (acute
phase), participants were seen on a weekly
basis. During the long-term phase, visit intervals were every 3 months until either study
completion (24 months) or study discontinuation. Throughout the study, children received
twice-a-day dosing of atomoxetine (morning
and late afternoon) with a target dose of 1.25
mg/kg per day (mean final dose = 1.13, SD =
0.45). The CHQ was completed at baseline,
after acute treatment (10 weeks or discontinuation) and after long-term treatment (24 months
or discontinuation). Clinician ratings on the
ADHD-RS were obtained to examine severity
of core ADHD symptoms at each visit during
the acute and long-term treatment phases.
Children were not permitted to begin new
psychotropic medication treatments during
the trial.
Data analyses
To examine baseline HRQL, t scores were
calculated for the ADHD sample using agebased norms provided in the CHQ user’s manual (Landgraf et al. 1996). All acute-phase
participants with a baseline CHQ score were
included in this analysis regardless of whether
or not they completed the long-term study.
Due to the longitudinal nature of the study,
age-based norms also were used in all subsequent analyses.
Analyses examining the response of treatment included all participants who completed
long-term treatment. The analysis sample was
restricted to this particular group because the
primary interest of this study was long-term
effects of atomoxetine treatment, and the acute
effects from double-blind placebo controlled
trials of atomoxetine have been described elsewhere (Michelson et al. 2001; Perwien et al.
2004). Due to the sparseness of the HRQL data
collection points, the primary assessment was
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based on change scores between HRQL measurement points rather than employing repeated measures models. A sensitivity
analysis, using repeated measures models,
was also conducted. The change scores computed included: (1) Baseline to acute-phase
end point and (2) acute-phase end point to the
end of the long-term treatment phase. Using
intent-to-treat analyses, paired t-tests were
employed to assess whether changes were statistically different from 0 for completers (i.e.,
participants with 24 months of treatment). To
understand better HRQL changes for participants who discontinued the investigation prematurely, secondary analyses were conducted
for participants who discontinued long-term
treatment (6 months and <24 months).
To assess the clinical meaningfulness of the
change scores, response rates were calculated.
Although there is no gold standard approach
to dichotomizing scores into response categories, participants were labeled as responders
if they had an increase of at least one standard
error of measurement (SEM) in their CHQ psychosocial summary score. The SEM, the standard deviation multiplied by the square root of
1 minus the reliability coefficient, represents a
change above and beyond that expected by
chance for an individual (Wyrwich et al. 1999).
Compared to response definitions based on t
scores, this approach reduces problems due to
participant baseline scores in or near the normative range. Based on the SEM criterion, participants were categorized into four mutually
exclusive groups: (1) Acute and long-term
treatment responder, (2) acute treatment responder only, (3) long-term treatment responder only, and (4) nonresponder. Because the
SEM criterion simply indicates individual improvement as opposed to “normal functioning,” percentages of participants within the
normative range (within 1 and 1.5 standard deviations of the normed mean) also are reported.
Last, potential predictors of changes during
the long-term phase of the study were assessed. ANOVA models were utilized to assess
long-term changes with the following dependent variables: Investigational site, acute end
point CHQ and ADHD-RS scores, age, gender,
race, ADHD subtype, oppositional defiant disorder diagnosis, and previous stimulant use.
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RESULTS
Participant characteristics
Of the 912 participants originally enrolled in
the trial, 80% (n = 728) completed the 10 weeks
of atomoxetine treatment (“acute participants”), 65% (n = 591) completed at least 6
months of treatment (“long-term participants”), and 34% (n = 312) completed the
entire 24-month study (“completers”). Participant data for each phase of the study including the number of participants retained at each
phase of the trial and the most common reasons for study discontinuation are presented
in Fig. 1.
Table 1 presents characteristics of acute participants, long-term participants, and completers. As shown in Fig. 2, participants in the
present study had baseline CHQ scores that
were significantly lower (indicating worse
HRQL) compared to normative data (Landgraf
et al. 1996). Because the CHQ assesses the past
4 weeks and some long-term participants (n =
209) and completers (n = 132) were treated
with stimulant medications within this timeframe, it was possible that these participants
had different baseline HRQL scores compared
to untreated participants due to having received treatment for ADHD. To examine this
issue, participants were divided into two
groups: Those taking a stimulant within 30
days prior to baseline assessment and those
who had not received any stimulant medications. Because there was no significant difference between the groups in baseline
psychosocial HRQL (t = 1.55, p = 0.12), all
other analyses employed the combined group.

Treatment outcomes
Table 2 summarizes HRQL and ADHD core
symptom baseline and change scores for the
completers. Following acute treatment with
atomoxetine, significant improvements were
observed on the psychosocial summary scale
(t statistic = 19.1, p < 0.01) as well as all psychosocial domains (Table 2). Improvements on
the psychosocial summary scale were maintained following long-term treatment (t = 0.4, p
= 0.71) and psychosocial subscale improve-
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ments were either maintained or slightly improved after 24 months of treatment (Table 2).
Compared to the magnitude of change on the
psychosocial summary scale between baseline
and acute phases, the magnitude of change
from acute to long-term was relatively small.
However, the 24-month scores for the psychosocial summary scale and all psychosocial
domains represent significant improvement
over the study entry scores. The pattern of
HRQL improvements was consistent with
those found for core ADHD symptoms. Specifically, clinician ratings based on parent interviews (ADHD-RS Total) and direct parent
reports (CPRS) of ADHD symptoms indicate
significant improvement after acute treatment
(t = 39.6, p < 0.01 and t = 33.2, p < 0.01, respectively), and these improvements were
maintained or slightly improved after longterm treatment (ADHD-RS Total t = 2.7, p =
0.01 and CPRS t = 1.2, p = 0.23). As expected,
no significant improvements were found on
the CHQ Physical Summary Scale or its related
domain subscales after acute or long-term
treatment.
As noted earlier, 279 long-term participants
discontinued treatment prior to the end of the
24-month study and end point CHQ measurements were available for 182 of these cases. For
these participants, psychosocial functioning
after long-term treatment declined from the
levels observed at the end of the acute phase
(psychosocial summary score mean change =
7.7, SD = 14.4, t = 7.7, p < 0.01). However,
the end point scores still represent an improvement from the original baseline (M = 6.0, SD =
14.6, t = 5.5, p < 0.01). Repeated measures
analysis employing all patients was performed
as a sensitivity analysis for the psychosocial
summary score and showed a similar pattern
as the primary assessment: A significant increase during the acute phase (p < 0.001) followed by stability from the acute to long-term
phase (p = 0.360).
Assessment of predictors did not yield consistent results across analyses. Oppositional
defiant disorder, past treatment with stimulants, age, prior HRQL ratings, and ADHD
symptoms were all significant predictors (p <
0.05) of long term improvement in either the
analysis of completers or of all long term par-
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Assessed for eligibility
(n = 1046)

Excluded from study
(n = 132)
Did not meet inclusion criteria (n = 83)
Refused to participate (n = 32)
Other reasons (n = 17)

Acute Treatment
Received treatment (n = 912)
Did not receive treatment (n = 2)

Acute Treatment Follow-Up
Completed treatment (n = 728)
Lost to follow-up (n = 10)
Discontinued treatment (n = 174):
Lack of efficacy (n = 97)
Adverse event (n = 21)
Protocol violation (n = 10)
Personal conflict/patient decision (n = 34)
Other (n = 12)

Long-Term Treatment
Received treatment (n = 591)
Did not receive long-term treatment (i.e., discontinued at end of or
after acute treatment, but prior to 6 months of treatment) (n = 137)
Lack of efficacy (n = 55)
Adverse event (n = 15)
Relapse (n = 21)
Protocol violation (n = 13)
Personal conflict/patient decision (n = 12)
Other (n = 21)

Long-Term Follow-Up
Completed long-term treatment (n = 312)
Lost to follow-up (n = 32)
Discontinued treatment (n = 247)
Lack of efficacy (n = 85)
Adverse event (n = 15)
Relapse (n = 24)
Protocol violation (n = 30)
Personal conflict/patient decision (n = 52)
Other (n = 41)

HRQL Completers Analyses
Excluded from analyses due to missing CHQ data (n = 17)
FIG. 1. Flow diagram of trial phases. CHQ = The Child Health Questionnaire; HRQL = health-related quality of life.
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TABLE 1. SAMPLE CHARACTERISTICS

Age, mean (SD)
Male
Ethnicity
White non-Hispanic
Hispanic
African American
Other
ADHD subtype
Hyperactive/impulsive
Inattentive
Mixed
Oppositional defiant disorder
History of stimulant treatment
Family history of ADHD
ADHD-RS t score (SD)

Acute participants
(n = 728)

Long-term participants
(n = 591)

Completers
(n = 312)

11.1 (2.8)
76.1%

11.1 (2.7)
76.5%

10.9 (2.6)
78.2%

82.8%
7.3%
5.6%a
4.3%

82.6%
7.6%
5.2%b
4.6%

83.7%
8.3%
2.6%a,b
5.5%

3.3%
35.0%
61.7%
37.2%a
75.6%
55.1%
78.8 (11.4)

3.0%
35.9%
61.1%
36.0%b
75.4%
54.4%
78.7 (11.4)

4.2%
35.9%
59.9%
32.1%a,b
76.5%
56.9%
78.1 (11.9)

Acute participants = participants who completed acute (10 weeks) of treatment; long-term participants = participants who completed at least 6 months of atomoxetine treatment; completers = participants who completed the entire 24-month study.
SD = standard deviation; ADHD = attention-deficit/hyperactivity disorder; ADHD-RS = ADHD Rating Scale.
aSignificant differences (p < 0.05) between completers and acute participants who were not completers.
bSignificant differences (p < 0.05) between completers and long-term participants who were not completers.
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FIG. 2. Baseline Child Health Questionnaire t scores for acute participants.

14366C08.pgs

12/18/06

11:43 AM

Page 720

720

PERWIEN ET AL.
TABLE 2. SUMMARY OF HRQL BASELINE AND CHANGE SCORES IN ADHD FOR COMPLETERS

Outcome measure
CHQ t scores (age-based)
Physical summary
Psychosocial summary
Behavior
Family activities
Parental impact–emotional
Parental impact–time
Role–emotional/behavioral
Self esteem
Mental health

n

Baseline
mean (SD)

Baseline to acute
change
mean (SD)

281
281
294
294
292
294
295
292
293

53.2 (7.9)
29.0 (13.1)
32.5 (12.3)
29.9 (14.1)
30.6 (10.8)
39.4 (11.6)
32.1 (19.3)
39.6 (11.9)
42.4 (13.6)

0.8 (8.6)
15.1 (13.3)
13.6 (11.1)
12.2 (13.4)
10.8 (13.4)
8.0 (12.5)
14.2 (21.0)
7.9 (12.1)
7.5 (14.0)

p

Acute to long-term
change
mean (SD)

p

0.117
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001

0.1 (8.1)
0.2 (11.2)
0.1 (9.4)
0.6 (11.5)
2.5 (14.0)
1.2 (11.4)
0.4 (15.2)
0.8 (11.8)
0.7 (11.0)

0.769
0.709
0.813
0.375
0.003
0.067
0.682
0.260
0.249

All patients with a baseline, acute treatment, and 24-month, long-term treatment score were included in the analysis.
SD = standard deviation; CHQ = Child Health Questionnaire; HRQL = health-related quality of life; ADHD = attention-deficit/hyperactivity disorder.

ticipants. For the completers, lack of prior
stimulant use, older age, less severe ADHD
symptoms at acute treatment end point, and
worse HRQL at acute treatment end point
were predictive of greater HRQL improvements. In examining all long-term participants, only worse HRQL following acute
treatment and the lack of oppositional defiant
disorder were predictive of more improved
HRQL.

cally, 67.3% (n = 189) and 80.1% (n = 225) of
these participants were within the normative
range using 1.0 and 1.5 SD range definitions,
respectively.

Response rates

Responder category

Using the response definition of an improvement in the psychosocial summary score
of at least one SEM, the majority of completers
were responders at the end of long-term treatment (Table 3). A total of 81.1% (n = 228) of the
completers were responders at the end of the
acute phase and 78.3% (n = 220) were responders after 24 months of treatment. Of the completers who responded after acute treatment,
86% (n = 196) continued to meet response criteria at the end of the study. Consistent with
response rate data for the completers, the majority of long-term participants met response
criteria at their final measurement (Table 3).
Of the long-term participants who were responders after the acute phase, 78.4% (n = 283)
continued to meet response criteria at end
point. Using t scores to examine response
rates, the majority of completers were responders following long-term treatment. Specifi-

Acute and long-term
treatment responder
Acute treatment only
responder
Long-term treatment only
responder
Nonresponder

TABLE 3. RESPONSE RATES FOR LONG-TERM PARTICIPANTS
AND COMPLETERS
Long-term
participants
(n = 456)

Completers
(n = 281)

62%

70%

17%

11%

8%

9%

13%

10%

Long-term participants = participants completing at
least 6 months of treatment; completers = participants
completing the entire 24-month study.
Response definition is based on the following criterion: a baseline to end point increase of at least one standard error of measurement (SEM) in CHQ psychosocial
summary score.
Acute and long-term treatment responder = participant responded after both the acute (10 weeks of treatment) and long-term treatment phases; acute treatment
only responder = participant responded after acute treatment but not after long-term treatment; long-term treatment only responder = participant responded after
long-term treatment but not after acute treatment; nonresponder = participant did not respond after acute or
long-term treatment.
CHQ = Child Health Questionnaire.
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DISCUSSION
At baseline, participants in this study were
experiencing significantly worse HRQL in
areas of psychosocial health compared to normative data. These findings are consistent
with other investigations (Landgraf et al. 1996;
Sawyer et al. 2002), and indicate that HRQL is
an area of concern for children with ADHD. In
addition, research indicates that HRQL is an
outcome that is not fully captured by the measurement of core ADHD symptomatology
(Matza et al. 2004). Therefore, the assessment
of HRQL should be viewed as a complementary procedure because HRQL represents a domain beyond traditional health status (e.g.,
ADHD core symptoms) by examining the subjective impact of a disorder. In fact, the AAP
also has recognized the importance of evaluating treatment across outcome domains,
including behavioral, academic, and psychosocial functioning (American Academy of
Pediatrics 2001). This type of multidimensional evaluation is likely to capture a full picture of treatment effectiveness including
meaningful HRQL outcomes such as social
functioning, family relationships, and psychological functioning.
In terms of outcomes of treatment with
atomoxetine, findings from this study add to
previously published data from acute, doubleblind placebo controlled clinical trials. These
trials, which have examined treatment effects
over relatively short periods of time (i.e., 8–10
weeks), support the efficacy of atomoxetine on
core ADHD symptoms as well as HRQL outcomes (Michelson et al. 2001; Perwien et al.
2004). The present study further supports earlier results by indicating that the HRQL improvements observed after acute treatment
with atomoxetine were generally maintained.
These data suggest that improvements found
after acute treatment were durable rather than
transitory. This pattern is consistent with
changes found for core ADHD symptoms. Finally, consistent with the symptoms of the disorder and data previously reported by
Perwien et al. (2004), HRQL improvements
were specific to areas of psychosocial rather
than physical health.
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Although some improvement was observed
from acute to long-term end point related to
the impact of ADHD on parents emotional adjustment, the majority of psychosocial HRQL
domains remained stable. One possibility is
that the failure to document further improvement may be due to ceiling effects and/or response shift. In a previous study (Perwien et
al. 2004), less psychosocial impairment at baseline was associated with less improvement following acute treatment with atomoxetine.
Thus, participants who evidenced better baseline HRQL scores were more limited in the
amount of improvement they could experience compared to participants who had worse
baseline scores. Therefore, it is possible that
participants in the present study who had high
HRQL at the beginning of the study had less
opportunity to improve significantly beyond
their acute scores. Response shift offers another explanation as to why there were not
further improvements from acute to long-term
treatment for the majority of psychosocial
health scales. It has been defined as, “a change
in the meaning of one’s self-evaluation of
quality of life (QOL) as a result of changes in
internal standards, values, and the conceptualization of QOL” (Sprangers and Schwartz 2000,
p. 14) following a change in health status. Parents in this study may have experienced response shift because their children’s health
status (i.e., ADHD core symptoms) improved,
resulting in a change in their internal standard
of HRQL measurement (recalibration). If the
recalibration were more stringent, it would be
more difficult to demonstrate improvement
over the course of long-term treatment.
The findings of this study should be interpreted with some caution due to the openlabel study design and the attrition rate.
Despite the open-label design, however, the
acute findings were consistent with doubleblind placebo controlled trials, suggesting that
the design did not unduly bias the results. Furthermore, it could be hypothesized that if the
influence of receiving a medication overly influenced perceived HRQL, treatment effects
might be less likely to be maintained because
the novelty of the treatment would decrease
over time. Attrition rates are generally a chal-
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lenge for long-term treatment studies, and the
present investigation is no exception. In this
study, only 52.8% of participants who began
long-term treatment completed the full 24month study and only 34.2% of the patients
that began acute treatment finished the full 24months of the study. It is possible that participants who completed the study were the most
receptive to treatment with atomoxetine. In
fact, those who remained in the study for the
full 24-month duration had greater improvements on HRQL compared to those who discontinued participation prematurely.
Several unanswered issues remain and are
of potential interest for future investigation.
For example, whether HRQL improvements
plateau or fluctuate following long-term treatment cannot be determined from this study
because of the limited measurement points
(i.e., baseline, acute end point, long-term end
point). Future studies should include children’s perceptions of their own HRQL. Including both parent and child informants would
not only provide a more complete picture of
the effect of treatment on HRQL, but would
also give insight into the consistency between
parent and child reports for children with
ADHD. In fact, some studies indicate that parents and children have different perceptions of
children’s HRQL (Vogels et al. 1998; Sawyer et
al. 1999; Levi and Drotar 1999).
Another area for future investigation is the
effect of multimodal treatment. Although
the MTA study (MTA Cooperative Group
1999) did not indicate superior effects for the
combined treatment arm (medication plus behavior therapy) compared to optimally administered medication alone, it is possible that
some of the HRQL outcomes may be amenable
to combination treatments that include a psychotherapeutic component. In addition, additional study is needed to assess potential
predictors of improvement further in HRQL.
Finally, atomoxetine appears to be a particularly attractive medication intervention because it does not have some of the potential
limitations of stimulant medications (Kratochvil et al. 2003) and appears to provide continuous symptom improvement (Kelsey et al.
2004). Although this study cannot address
whether or not these characteristics of atomox-
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etine have a positive effect on HRQL, it is possible that these factors play a role in improving
HRQL. For example, continuous symptom relief may allow for a child to have improved interactions with family members which may, in
turn, enhance family functioning aspects of
HRQL.
Notwithstanding the aforementioned limitations and examined in conjunction with previous findings (Michelson et al. 2001; Perwien
et al. 2004), this study supports the positive response to atomoxetine treatment on HRQL in
children and adolescents. As these data indicate, improved HRQL is present following
acute treatment and is maintained over longterm treatment. Although medications for
chronic conditions, such as ADHD, are developed to improve specific symptoms and
evaluated on disease-related health status
measures (e.g., core ADHD symptoms), successful treatment may be better indicated by
improvement in both health status and functional outcomes. This may be especially important in chronic conditions that have been
documented to be associated with relatively
poor HRQL. The present investigation provides a model for evaluating ADHD treatment
on domains of functioning not previously documented in other studies.
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